Publication
Article
Pharmacy Times
Author(s):
Multiple sclerosis is an incurable immune-mediated inflammatory disease that produces symptomatic episodes months or years apart in different anatomic locations.
Multiple sclerosis (MS) is an incurable immune-mediated inflammatory disease that produces symptomatic episodes months or years apart in different anatomic locations. It attacks myelinated axons in the central nervous system (CNS), destroying the myelin and the axon to varying degrees. Over time, MS causes significant physical disability; within 20 to 25 years, more than 30% of patients become disabled.1,2 Table 13-6 lists symptoms; note that each patient’s presentation differs.
Approximately 20% of patients present with optic neuritis as their initial demyelinating symptom, while roughly 40% of patients develop this after diagnosis. Patients report loss of vision or color vision in the affected eye(s) and ocular pain, especially when the affected eye moves. Some patients also develop phosphenes (transient light flashes or black squares) before, during, even months after optic neuritis events.3,4
MS presents in several forms (Table 21,3,7,8), reflecting clinical relapses, time to disease progression, and lesion development on magnetic resonance imaging (MRI). Nearly 50% of patients initially diagnosed with relapsing-remitting MS (RRMS) convert to a secondary- progressive pattern within 10 to 15 years. This pattern may not include relapses, but it is characterized by progression over years, with increasing disability. Treatment with disease-modifying therapies (DMTs), however, may slow the progression. Unlike RRMS, secondary-progressive MS without relapses is often refractory to currently available DMTs.1,3,7,8
Table 2. Types of Multiple Sclerosis
Types of Multiple Sclerosis
Statistics and Important Points
Relapsing remitting MS
Progressive forms of MS
Secondary-progressive MS
Primary-progressive MS
Progressive-relapsing MS
Progressive-relapsing benign MS
DMT = disease-modifying therapy; RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary-progressive multiple sclerosis.Adapted from references 1, 3, 7, and 8.
MRI, a nonspecific imaging test, is preferred to confirm MS and monitor disease progression in the brain and the spinal cord. Clinicians also use MRI and the evoked potentials test, which records the timing of CNS responses to specific stimuli, to measure treatment response and evaluate MS.7
Treatment
Early aggressive treatment with DMTs may slow disease progression and irreversible neurologic damage. Although efficacy data can be used to determine each agent’s ability to prevent clinical relapses and reduce inflammatory activity detected by MRI, no single biomarker predicts a patient’s response to treatment.3,9
Treatment teams face several hurdles when caring for patients with MS. Few guidelines, however, address the wide variations in presentation well or cover all approved agents.10 Pharmacists may find it helpful to group the 13 FDA-approved agents based on their approval and administration routes:
Mitoxantrone is also approved for managing MS, but its association with cardiotoxicity and secondary leukemias limits its clinical use.18 Few head-to-head clinical trials compare the DMTs.7 When deciding on a course of treatment, neurologists consider efficacy, safety, tolerability, patient preference, and convenience,24 and share decision making with the patient.9
Adherence and MS-Related Problems
All DMTs produce adverse effects that contribute to nonadherence.24 Pharmacists need to counsel patients that it takes time to adjust to medication. Patients who experience intolerable adverse effects or show significant laboratory abnormalities, a poor or dwindling response, evidence of progression, or new activity on MRIs may need to switch therapies.25
Many of the medications used to treat MS are dispensed from specialty pharmacies or administered in physicians’ offices. Therefore, community pharmacists are more likely to deal with patients’ MS-related problems. Table 326-29 describes MS’s common symptoms and the medications for treating them.
End Note
Patients with MS need early intervention. The Multiple Sclerosis Coalition’s 2014 consensus document (updated in 2016) supports early, wide access to FDA-approved DMTs.30 It is an essential (and free) reference for pharmacists.
Ms. Wick is a visiting professor at the University of Connecticut School of Pharmacy.
References